About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Company Statements 2018
Biocon Biologics
/
News – Posts
/
Company Statements
/
Company Statements 2018
Biosimilar Trastuzumab Co-Developed by Biocon Receives Approval in the EU
Wed, 19-Dec-2018
Posted by: Biocon Biologics
No Comments
Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU
Fri, 30-Nov-2018
Posted by: Biocon Biologics
No Comments
Biocon Update on Insulin Glargine
Sat, 02-Jun-2018
Posted by: Biocon Biologics
No Comments
Mylan and Biocon seek to accelerate introduction of Adalimumab biosimilar in EU
Wed, 11-Apr-2018
Posted by: Biocon Biologics
No Comments
Update on Company Statement on US-FDA Inspection at Biocon Malaysia
Tue, 13-Mar-2018
Posted by: Biocon Biologics
No Comments
Company Statement on US-FDA Inspection at Biocon Malaysia
Wed, 21-Feb-2018
Posted by: Biocon Biologics
No Comments
